Clinical Trial Update: Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating apatinib for radioactive iodine-refractory differentiated thyroid cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Differentiated Thyroid Cancer | Phase 3 | Status: UNKNOWN